Evidence-based oncology mitomycin C provides little additional benefit in the treatment of carcinoma of unknown primary site: Abstracted from: Assersohn L, Norman AR, Cunningham D et al. A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. European Journal of Cancer 2003; 39: 1121–1128

✍ Scribed by Jonathan E Dowell

• Book ID: 116394858
• Publisher: Elsevier Science
• Year: 2003
• Tongue: English
• Weight: 65 KB
• Volume: 29
• Category: Article
• ISSN: 0305-7372
• DOI: 10.1016/j.ctrv.2003.09.001